About Us

We are an unparalleled biopharmaceutical company.


2011 ~ Present

07Merger and listing on KOSPI
12 Affiliated company, Aprogen Pharmaceuticals, Merger with 'Aprogen Biologics'
11Started commercialization of GS071
08Appointed Seungho Rhee as CEO
07Completed phase nonclinical trials for AP096
03Completed phase nonclinical trials for AP056
01Obtained domestic Food and Drug Safety (MFDS) cGMP certification
01First Korean Biopharmaceutical Company to be listed as a Unicorn
(private ventures with $1 billion+ in valuations)
01Osong Plant Expansion
09Completed phase 3 clinical trials for GS071 in US
05Completed phase 1 clinical trials for AP063 in US
연혁 이미지
04Completed construction of Osong Plant
09Received approval of GS071 for Japan (PMDA)
07Started Osong Plant construction
05Acquired Innovative SME Certificate (Inno-Biz) from Ministry of SMEs and Startups
05Acquired R&D Venture Enterprise Certificate from Korea Technology Finance Corporation
연혁 이미지
10Submitted MAA (Marketing Authorization Application) for GS071 to the PMDA
09Completed phase 3 clinical trials for GS071 in Japan
06Contracted long-term supply agreement for GS071 with Nichi-Iko Pharmaceuticals Co., Ltd.
03Relocated headquarters to B1, Halla Sigma Valley, 545, Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do
연혁 이미지
04Established Aprogen Biologics Inc. for constructing Osong Plant
02Contracted global license rights for GS071 with Nichi-Iko Pharmaceuticals Co., Ltd.
11Relocated headquarters to Inno-Biz Park, Hannam University
11Completed phase 1 clinical trials for GS071 in Japan
10Acquired property for Osong Plant in Osong Biovalley, Chungbuk
03Completed phase 1 clinical trials for GS071 Korea
연혁 이미지
11Signed agreement between Schnell Life Sciences Inc. and Binex Co., Ltd. for joint pursue of license for GS071 in Russia, Turkey, and the Middle East
08Contracted AP063 distribution rights for Korea to Schnell Life Sciences Inc.
03Finished construction and relocated R&D labs and clinical scale production facility to Seongnam
03Received 2nd round of funding from Nichi-Iko Pharmaceuticals Co., Ltd.
연혁 이미지